Hyperion Therapeutics, Inc. announced top-line results from a phase I study of HPN-100 in patients with liver cirrhosis. The data were presented as part of the 2009 Digestive Disease Week meeting. The abstract is titled “Pharmacokinetic (PK) and Safety Analyses of a Novel Ammonia-Reducing Agent in Healthy Adults and Patients with Cirrhosis.
Lees meer..

Two studies from AstraZeneca (NYSE: AZN) show that symptomatic gastroesophageal reflux disease (GERD) patients treated with NEXIUM(R) (esomeprazole magnesium) 20 mg daily experienced greater relief from nighttime heartburn and GERD-related sleep disturbances compared with patients taking placebo over four weeks(1). NEXIUM 20 mg is indicated for the treatment of heartburn and other symptoms associated with GERD.
Lees meer..

Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced that the U.S. Food and Drug Administration (FDA) has approved the design of pivotal, Phase 2b/3 clinical trials evaluating its lead product ATPace(TM) as an antiarrhytmic drug for the acute treatment of patients with paroxysmal supraventricular tachycardia (PSVT) under the Special Protocol Assessment (SPA) process. ATPace(TM) is a novel stable liquid formulation of adenosine 5′-triphosphate (ATP).
Lees meer..

TeraMedica Healthcare Technology announced, along with partner, Sun Microsystems, that the two companies will be offering a pre-configured solution for viewing and managing clinical images originating from different modalities and providers to bring secure, consistent image sharing to point-of-care. “The Evercore® Enterprise Imaging Interchange combines Sun’s Master Patient Index and Enterprise Services Bus with the Evercore - UnivisionTM. and SmartstoreTM modules.
Lees meer..

PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced that it has submitted a proposal to the Biomedical Advanced Research and Development Authority (BARDA) in response to a Broad Agency Announcement (BAA-BARDA-09-34) for advanced research and development of medical countermeasures for chemical, biological, radiological and nuclear threats.
Lees meer..

NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced that the Office of Orphan Product Development (OOPD) of the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Qutenza(TM) (formerly NGX-4010), a high concentration capsaicin dermal patch for the management of neuropathic pain in patients with postherpetic neuralgia (PHN).
Lees meer..

New long-term findings from the Phase 3b study of patients with moderately to severely active Crohn’s disease having inadequate response to conventional therapies, but naive to immunomodulators and biologic therapy, were presented at Digestive Disease Week today. Data from the SONIC study showed that a greater proportion of patients receiving REMICADE (infliximab) maintained steroid-free remission at one year, compared with patients receiving azathioprine alone.
Lees meer..

This month’s Journal of Aerosol Medicine and Pulmonary Drug Delivery features positive Phase Ib clinical trial results for PARI Pharma’s L-CsA, inhaled liposomal cyclosporine A.
Lees meer..

As the number of food and beverage products sweetened with stevia-based ingredients continues to grow in the United States and worldwide, the U.S. Pharmacopeial (USP) Convention announces that new reference standards for Rebaudioside A and Stevioside are now available.
Lees meer..

ChemoCentryx, Inc.
Lees meer..